NCT01411436View on ClinicalTrials.gov

Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan

CompletedOBSERVATIONAL
Enrollment

1,637

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

March 31, 2014

Study Completion Date

February 28, 2015

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Sorafenib (Nexavar, BAY43-9006)

Patients who have received Nexavar for unresectable HCC

Trial Locations (1)

Unknown

Many Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01411436 - Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan | Biotech Hunter | Biotech Hunter